FDA Postmarket Cybersecurity for NeuroTech & BCIs
Postmarket cybersecurity for BCIs, neurostimulators, and DBS systems. SBOM monitoring, CVD, neural data protection, and safe updates for implanted devices.
Aligned to FDA's February 3, 2026 premarket cybersecurity guidance.
Neural implants stay in patients for many years. Brain-computer interfaces (BCIs), deep brain stimulators, and spinal cord stimulators keep running long after the submission is filed. Section 524B requires a plan to monitor, identify, and address postmarket vulnerabilities, including coordinated vulnerability disclosure. FDA guidance also recommends SBOM monitoring and a documented update plan. For neural devices, patient safety comes first: a vulnerability can affect stimulation, recorded neural data, or the device a patient uses to communicate.
We monitor the SBOM across the implant, the external processor, the clinician programmer, the patient app, and the cloud. Each new CVE gets a written exploitability decision your team reviews and approves. We set up or run a coordinated vulnerability disclosure program with clear intake, triage, and disclosure steps. We plan updates for implanted hardware that cannot be swapped easily, including what happens if an update is interrupted. We also review how neural recordings are stored, shared for research, and retained, because neural data cannot be changed once exposed. Decisions on risk acceptance stay with the manufacturer.
Layers we exercise in this engagement
The neurotech / bci system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this fda postmarket cybersecurity.
- 01Cloud and research data Tested
- 02Patient app Tested
- 03Clinician programmer Tested
- 04External processor Tested
- 05Implant fleet Tested
- 06Vulnerability intake (CVD) Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
FDA Postmarket Cybersecurity engagement, end to end
Four phases, fixed fee, scoped to neurotech / bci architecture from kickoff onward.
- 01
Deployed-system scope
Confirm supported software versions, connected components, deployment constraints, and manufacturer owners.
- 02
Monitoring and technical review
Review vulnerability sources against deployed components. Record applicability and exploitability evidence for manufacturer approval.
- 03
Coordinated vulnerability disclosure
Set up or operate intake, triage, and disclosure procedures connected to your change-control process.
- 04
Field response and records
Document remediation options, update and recovery plans, affected configurations, and communications. The manufacturer approves risk, clinical, and reporting decisions.
What we see in NeuroTech / BCI fda postmarket cybersecurity
The patterns we hit in this segment, this service, again and again.
Day-one SBOM not maintained across the BCI system
The submitted SBOM can cover the implant but miss the external processor, phone app, or cloud. New CVEs in those parts then go unreviewed.
No defined update path for implanted hardware
An update plan can assume devices are easy to reach. Implants need a tested plan for interrupted updates, rollback protection, and patients who miss clinic visits.
Neural data handling not covered by the postmarket plan
Research exports and cloud retention of neural recordings can fall outside postmarket monitoring. We check that access, retention, and disclosure steps cover them.
Vulnerability intake without a patient-safety triage step
Reports can be triaged like ordinary IT bugs. We add a step that asks first whether stimulation, decoded output, or therapy continuity could be affected.
NeuroTech / BCI reading and listening
- Device areaNeuroTechnology & Brain-Computer Interfaces cybersecurity
- ServiceMedical Device Penetration Testing for NeuroTech & BCIs
- ServiceThreat Modeling for NeuroTech & BCIs
- ArticleBrainjacking: Neurotech Cybersecurity Risks and FDA Rules
- ArticleMedical Device Cybersecurity From Animal Studies to Human Trials
- ArticleQ-Day: A Present-Day FDA Compliance Gap
- PodcastFrom Science Fiction to Visual Prosthesis with Frederik Ceyssens
- PodcastScience Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly what reviewers want to see."
Standard FDA Postmarket Cybersecurity deliverables
The same deliverables the parent FDA Postmarket Cybersecurity service ships with - tuned to your neurotech / bci architecture.
- TPLC Partnership: Annual retainer covering one product line through Total Product Lifecycle - SBOM monitoring, CISA-KEV tracking, full CVD process operation, quarterly penetration tests, and ongoing FDA/EU regulatory updates. One predictable fee, one accountable team, zero gaps between cleared release and end-of-support.
- SBOM monitoring: Section 524B requires manufacturers to maintain and update SBOMs continuously. We track every component for newly disclosed CVEs and flag them before they become reportable vulnerabilities.
- CVD program (Coordinated Vulnerability Disclosure): We manage the full CVD process - researcher intake, triage, fix timeline, and FDA notification - so your team doesn't face a public disclosure event without a prepared response. The FDA's postmarket reporting timelines are built into every engagement.
- Threat monitoring: We proactively monitor your device's ecosystem daily, with a named engineer triaging every match.
- Incident response: Response plans aligned with the FDA's postmarket timelines for uncontrolled risks (customer communication within 30 days, a fix within 60 days) - with audit-ready documentation from day one.
- Patch validation: Every patch goes through validation testing before deployment - so you can demonstrate to FDA that the fix didn't introduce new risk.
What lands in your eSTAR submission
Documents structured for the cybersecurity attachments of your submission - no reformatting on your side.
- TPLC Partnership: Annual retainer covering one product line through Total Product Lifecycle - SBOM monitoring, CISA-KEV tracking, full CVD process operation, quarterly penetration tests, and ongoing FDA/EU regulatory updates. One predictable fee, one accountable team, zero gaps between cleared release and end-of-support.
- SBOM monitoring: Section 524B requires manufacturers to maintain and update SBOMs continuously. We track every component for newly disclosed CVEs and flag them before they become reportable vulnerabilities.
- CVD program (Coordinated Vulnerability Disclosure): We manage the full CVD process - researcher intake, triage, fix timeline, and FDA notification - so your team doesn't face a public disclosure event without a prepared response. The FDA's postmarket reporting timelines are built into every engagement.
- Threat monitoring: We proactively monitor your device's ecosystem daily, with a named engineer triaging every match.
- Incident response: Response plans aligned with the FDA's postmarket timelines for uncontrolled risks (customer communication within 30 days, a fix within 60 days) - with audit-ready documentation from day one.
Standards that apply
The NeuroTech / BCI baseline, plus the call-outs that matter for fda postmarket cybersecurity in this segment.
Segment-specific call-outs
Section 524B + FDA postmarket cybersecurity guidance
Section 524B requires the postmarket vulnerability plan. FDA guidance recommends how to monitor and remediate. We keep the two separate in your documents.
AAMI TIR97 + ISO/IEC 29147 and 30111
Used to structure postmarket risk management and the coordinated vulnerability disclosure program.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Manufacturer risk acceptance, clinical decisions, or regulatory reporting decisions
- Automatic VEX conclusions without device-specific evidence and manufacturer approval
- Clinical validation or general software testing
- Firmware implementation or penetration testing unless separately scoped
FDA Postmarket Cybersecurity for NeuroTech / BCI - FAQs
The questions buyers in this segment actually ask before scoping a fda postmarket cybersecurity engagement.
Go deeper on NeuroTech / BCI and postmarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
Medical device cybersecurity should scale with device risk. Christian Espinosa argues why meeting only the Section 524B minimum leaves patients and submissions exposed.
VEX resources for medical device teams: a document guide, SBOM comparison, and common assessment mistakes, with evidence-based status and regulatory context.
Medical device cybersecurity for nanotech neurostimulation: a fictional STRIDE threat model linking controller risks, patient harms, controls, and testing.
Other engagements for NeuroTech / BCI
Teams in this segment commonly bundle these alongside fda postmarket cybersecurity.
Keep going
Scope a FDA Postmarket Cybersecurity engagement for your neurotech / bci program.
A 30-minute discovery call with Christian Espinosa, Founder and CEO, and Kristy Kennedy, VP of Sales.